Extended Data Table 2 Summary of PK parameters for ABBV-706 conjugate, total antibody, and free Top1i payload in cycle 1 following Q3W dosing as monotherapy (geometric mean [arithmetic mean, %CV])

From: SEZ6-targeting antibody−drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial

  1. aTmax presented as median (minimum-maximum); reported as time relative to the end of infusion. bAUC504h = area under the concentration-time curve up to 504 hours. ct1/2 presented as harmonic mean (pseudo-standard deviation). dn = 101. en = 100. fn = 4. gn = 34. hn = 79. in = 57. jn = 13. kn = 10. lSample sizes differ between analytes due to the lack of sufficient samples to include in the non-compartmental analysis. Summaries include all viable PK parameters.
  2. Cmax, maximum observed concentration; CV, coefficient of variation; PK, pharmacokinetic; Q3W, every 3 weeks; t1/2, terminal phase elimination half-life; Tmax, time to Cmax; Top1i, topoisomerase 1 inhibitor.
Back to article page